107. Increased mortality among men aged 50 years old or above with elevated IgA anti-transglutaminase antibodies: NHANES III.
作者: Alberto Rubio-Tapia.;Jonas F Ludvigsson.;Rok Seon Choung.;Tricia L Brantner.;S Vincent Rajkumar.;Ola Landgren.;Joseph A Murray.
来源: BMC Gastroenterol. 2016年16卷1期136页
Immunoglobulin A (IgA) antibodies to tissue transglutaminase (tTG) are the serologic test of choice for diagnosing celiac disease (CD). Our aim was to determine if elevated IgA anti-tTG were associated with increased mortality risk.
108. Aryl Hydrocarbon Receptor Ligands in Cigarette Smoke Induce Production of Interleukin-22 to Promote Pancreatic Fibrosis in Models of Chronic Pancreatitis.
作者: Jing Xue.;Qinglan Zhao.;Vishal Sharma.;Linh P Nguyen.;Yvonne N Lee.;Kim L Pham.;Mouad Edderkaoui.;Stephen J Pandol.;Walter Park.;Aida Habtezion.
来源: Gastroenterology. 2016年151卷6期1206-1217页
Cigarette smoke has been identified as an independent risk factor for chronic pancreatitis (CP). Little is known about the mechanisms by which smoking promotes development of CP. We assessed the effects of aryl hydrocarbon receptor (AhR) ligands found in cigarette smoke on immune cell activation in humans and pancreatic fibrosis in animal models of CP.
110. Understanding and Preventing the Global Increase of Inflammatory Bowel Disease.
The inflammatory bowel diseases (IBDs) are contemporary conditions of industrialized societies. The prevalence of IBD continues to increase steadily in Western countries, and newly industrialized countries have a rapidly increasing incidence. The global spread of IBD appears to associate with Westernization of diets and environments, which affects the intestinal microbiome and increases the risk of IBD in genetically susceptible individuals. It is important to increase our understanding of these events to slow progression of IBD. We present a long-term plan to develop interventions that slow or stop the global increase in the incidence of IBD.
111. Diet as a Trigger or Therapy for Inflammatory Bowel Diseases.
The most common question asked by patients with inflammatory bowel disease (IBD) is, "Doctor, what should I eat?" Findings from epidemiology studies have indicated that diets high in animal fat and low in fruits and vegetables are the most common pattern associated with an increased risk of IBD. Low levels of vitamin D also appear to be a risk factor for IBD. In murine models, diets high in fat, especially saturated animal fats, also increase inflammation, whereas supplementation with omega 3 long-chain fatty acids protect against intestinal inflammation. Unfortunately, omega 3 supplements have not been shown to decrease the risk of relapse in patients with Crohn's disease. Dietary intervention studies have shown that enteral therapy, with defined formula diets, helps children with Crohn's disease and reduces inflammation and dysbiosis. Although fiber supplements have not been shown definitively to benefit patients with IBD, soluble fiber is the best way to generate short-chain fatty acids such as butyrate, which has anti-inflammatory effects. Addition of vitamin D and curcumin has been shown to increase the efficacy of IBD therapy. There is compelling evidence from animal models that emulsifiers in processed foods increase risk for IBD. We discuss current knowledge about popular diets, including the specific carbohydrate diet and diet low in fermentable oligo-, di-, and monosaccharides and polyols. We present findings from clinical and basic science studies to help gastroenterologists navigate diet as it relates to the management of IBD.
112. The incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: a population-base study.
作者: Abhasnee Sobhonslidsuk.;Kittiyod Poovorawan.;Ngamphol Soonthornworasiri.;Wirichada Pan-Ngum.;Kamthorn Phaosawasdi.
来源: BMC Gastroenterol. 2016年16卷1期135页
Toxic liver diseases are mainly caused by drug-induced liver injury (DILI). We assessed incidences and outcomes of DILI including associated factors for mortality.
113. Interleukin 1β Mediates Intestinal Inflammation in Mice and Patients With Interleukin 10 Receptor Deficiency.
作者: Dror S Shouval.;Amlan Biswas.;Yu Hui Kang.;Alexandra E Griffith.;Liza Konnikova.;Ivan D Mascanfroni.;Naresh S Redhu.;Sandra M Frei.;Michael Field.;Andria L Doty.;Jeffrey D Goldsmith.;Atul K Bhan.;Anthony Loizides.;Batia Weiss.;Baruch Yerushalmi.;Tadahiro Yanagi.;Xiuli Lui.;Francisco J Quintana.;Aleixo M Muise.;Christoph Klein.;Bruce H Horwitz.;Sarah C Glover.;Athos Bousvaros.;Scott B Snapper.
来源: Gastroenterology. 2016年151卷6期1100-1104页
Interleukin 10 receptor (IL10R)-deficient mice develop spontaneous colitis and, similarly, patients with loss-of-function mutations in IL10R develop severe infant-onset inflammatory bowel disease. Loss of IL10R signaling in mouse and human macrophages is associated with increased production of interleukin 1β. We demonstrated that innate immune production of IL1β mediates colitis in IL10R-deficient mice. Transfer of Il1r1-/- CD4+ T cells into Rag1-/-/Il10rb-/- mice reduced the severity of their colitis (compared to mice that received CD4+ T cells that express IL1R), accompanied by decreased production of interferon gamma, tumor necrosis factor-α, and IL17A. In macrophages from mice without disruption of IL10R signaling or from healthy humans (controls), incubation with IL10 reduced canonical activation of the inflammasome and production of IL1β through transcriptional and post-translational regulation of NLRP3. Lipopolysaccharide and adenosine triphosphate stimulation of macrophages from Il10rb-/- mice or IL10R-deficient patients resulted in increased production of IL1β. Moreover, in human IL10R-deficient macrophages, lipopolysaccharide stimulation alone triggered IL1β secretion via non-canonical, caspase 8-dependent activation of the inflammasome. We treated 2 IL10R-deficient patients with severe and treatment-refractory infant-onset inflammatory bowel disease with the IL1-receptor antagonist anakinra. Both patients had marked clinical, endoscopic, and histologic responses after 4-7 weeks. This treatment served as successful bridge to allogeneic hematopoietic stem cell transplantation in 1 patient. Our findings indicate that loss of IL10 signaling leads to intestinal inflammation, at least in part, through increased production of IL1 by innate immune cells, leading to activation of CD4+ T cells. Agents that block IL1 signaling might be used to treat patients with inflammatory bowel disease resulting from IL10R deficiency.
114. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice.
作者: Pouria Jandaghi.;Hamed S Najafabadi.;Andrea S Bauer.;Andreas I Papadakis.;Matteo Fassan.;Anita Hall.;Anie Monast.;Magnus von Knebel Doeberitz.;John P Neoptolemos.;Eithne Costello.;William Greenhalf.;Aldo Scarpa.;Bence Sipos.;Daniel Auld.;Mark Lathrop.;Morag Park.;Markus W Büchler.;Oliver Strobel.;Thilo Hackert.;Nathalia A Giese.;George Zogopoulos.;Veena Sangwan.;Sidong Huang.;Yasser Riazalhosseini.;Jörg D Hoheisel.
来源: Gastroenterology. 2016年151卷6期1218-1231页
Incidence of and mortality from pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, are almost equivalent, so better treatments are needed. We studied gene expression profiles of PDACs and the functions of genes with altered expression to identify new therapeutic targets.
115. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.
作者: Riad Salem.;Andrew C Gordon.;Samdeep Mouli.;Ryan Hickey.;Joseph Kallini.;Ahmed Gabr.;Mary F Mulcahy.;Talia Baker.;Michael Abecassis.;Frank H Miller.;Vahid Yaghmai.;Kent Sato.;Kush Desai.;Bartley Thornburg.;Al B Benson.;Alfred Rademaker.;Daniel Ganger.;Laura Kulik.;Robert J Lewandowski.
来源: Gastroenterology. 2016年151卷6期1155-1163.e2页
Conventional transarterial chemoembolization (cTACE) is used to treat patients with hepatocellular carcinoma (HCC). Radioembolization is a minimally invasive procedure that involves implantation of radioactive micron-sized particles loaded with yttrium-90 (Y90) inside the blood vessels that supply a tumor. We performed a randomized, phase 2 study to compare the effects of cTACE and Y90 radioembolization in patients with HCC.
116. In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.
作者: Jeffrey B Schwimmer.;Joel E Lavine.;Laura A Wilson.;Brent A Neuschwander-Tetri.;Stavra A Xanthakos.;Rohit Kohli.;Sarah E Barlow.;Miriam B Vos.;Saul J Karpen.;Jean P Molleston.;Peter F Whitington.;Philip Rosenthal.;Ajay K Jain.;Karen F Murray.;Elizabeth M Brunt.;David E Kleiner.;Mark L Van Natta.;Jeanne M Clark.;James Tonascia.;Edward Doo.; .
来源: Gastroenterology. 2016年151卷6期1141-1154.e9页
No treatment for nonalcoholic fatty liver disease (NAFLD) has been approved by regulatory agencies. We performed a randomized controlled trial to determine whether 52 weeks of cysteamine bitartrate delayed release (CBDR) reduces the severity of liver disease in children with NAFLD.
117. CagY Is an Immune-Sensitive Regulator of the Helicobacter pylori Type IV Secretion System.
作者: Roberto M Barrozo.;Lori M Hansen.;Anna M Lam.;Emma C Skoog.;Miriam E Martin.;Lucy P Cai.;Yong Lin.;Andreas Latoscha.;Sebastian Suerbaum.;Don R Canfield.;Jay V Solnick.
来源: Gastroenterology. 2016年151卷6期1164-1175.e3页
Peptic ulcer disease and gastric cancer are caused most often by Helicobacter pylori strains that harbor the cag pathogenicity island, which encodes a type IV secretion system (T4SS) that injects the CagA oncoprotein into host cells. cagY is an essential gene in the T4SS and has an unusual DNA repeat structure that predicts in-frame insertions and deletions. These cagY recombination events typically lead to a reduction in T4SS function in mouse and primate models. We examined the role of the immune response in cagY-dependent modulation of T4SS function.
118. Combination of Mass Cytometry and Imaging Analysis Reveals Origin, Location, and Functional Repopulation of Liver Myeloid Cells in Mice.
作者: Bruna Araujo David.;Rafael Machado Rezende.;Maísa Mota Antunes.;Mônica Morais Santos.;Maria Alice Freitas Lopes.;Ariane Barros Diniz.;Rafaela Vaz Sousa Pereira.;Sarah Cozzer Marchesi.;Débora Moreira Alvarenga.;Brenda Naemi Nakagaki.;Alan Moreira Araújo.;Daniela Silva Dos Reis.;Renata Monti Rocha.;Pedro Elias Marques.;Woo-Yong Lee.;Justin Deniset.;Pei Xiong Liew.;Stephen Rubino.;Laura Cox.;Vanessa Pinho.;Thiago Mattar Cunha.;Gabriel Rocha Fernandes.;André Gustavo Oliveira.;Mauro Martins Teixeira.;Paul Kubes.;Gustavo Batista Menezes.
来源: Gastroenterology. 2016年151卷6期1176-1191页
Resident macrophages are derived from yolk sac precursors and seed the liver during embryogenesis. Native cells may be replaced by bone marrow precursors during extensive injuries, irradiation, and infections. We investigated the liver populations of myeloid immune cells and their location, as well as the dynamics of phagocyte repopulation after full depletion. The effects on liver function due to the substitution of original phagocytes by bone marrow-derived surrogates were also examined.
119. Loss of Trefoil Factor 2 From Pancreatic Duct Glands Promotes Formation of Intraductal Papillary Mucinous Neoplasms in Mice.
作者: Junpei Yamaguchi.;Mari Mino-Kenudson.;Andrew S Liss.;Sanjib Chowdhury.;Timothy C Wang.;Carlos Fernández-Del Castillo.;Keith D Lillemoe.;Andrew L Warshaw.;Sarah P Thayer.
来源: Gastroenterology. 2016年151卷6期1232-1244.e10页
Little is known about the origin of pancreatic intraductal papillary mucinous neoplasms (IPMN). Pancreatic duct glands (PDGs) are gland-like outpouches budding off the main pancreatic ducts that function as a progenitor niche for the ductal epithelium; they express gastric mucins and have characteristics of side-branch IPMNs. We investigated whether PDGs are a precursor compartment for IPMNs and the role of Trefoil factor family 2 (TFF2)-a protein expressed by PDGs and the gastric mucosa that are involved in epithelial repair and tumor suppression.
120. Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal Cancer.
作者: Toshiaki Watanabe.;Yoichi Ajioka.;Keiichi Mitsuyama.;Kenji Watanabe.;Hiroyuki Hanai.;Hiroshi Nakase.;Reiko Kunisaki.;Keiji Matsuda.;Ryuichi Iwakiri.;Nobuyuki Hida.;Shinji Tanaka.;Yoshiaki Takeuchi.;Kazuo Ohtsuka.;Kazunari Murakami.;Kiyonori Kobayashi.;Yasushi Iwao.;Masakazu Nagahori.;Bunei Iizuka.;Keisuke Hata.;Masahiro Igarashi.;Ichiro Hirata.;Shin-Ei Kudo.;Takayuki Matsumoto.;Fumiaki Ueno.;Gen Watanabe.;Masahiro Ikegami.;Yoko Ito.;Koji Oba.;Eisuke Inoue.;Naoki Tomotsugu.;Toru Takebayashi.;Kenichi Sugihara.;Yasuo Suzuki.;Mamoru Watanabe.;Toshifumi Hibi.
来源: Gastroenterology. 2016年151卷6期1122-1130页
A random biopsy is recommended for surveillance of ulcerative colitis (UC)-associated colorectal cancer. However, a targeted biopsy might be more effective. We conducted a randomized controlled trial to compare rates of neoplasia detection by targeted vs random biopsies in patients with UC.
|